Breast Cancer
Recent findings from Italy illuminate research in breast cancer
Published in Cancer Weekly, August 29th, 2006
Study 1: Elderly breast cancer patients tolerated idarubicin (IDA) at the dose of 5 mg/day for 21 consecutive days but did not exhibit an improvement in efficacy.
According to a recent report, researchers in Italy conducted a study "to determine if protracted low-dose oral IDA, feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Elderly women ({{>=}}65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks."
"After the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-29)
More Articles from Cancer Weekly
- Cancer Therapy
Ambitious research program in pharmacogenetics aims to individualize cancer treatment - Colorectal Adenoma
Advanced colorectal adenoma recurrence risk reduced with high dry bean intake - Ovarian Cancer
Ovarian cancer risk potentially reduced with paracetamol use - Pancreatic Cancer
Pancreatic carcinogenesis possibly prevented by targeting nuclear factor kappa B - Acoustic Neuromas
House Clinic offers Gamma Knife technology as treatment for acoustic neuromas - Acute Myeloid Leukemia
Acute myeloid leukemia survival improved with high-dose cytosine arabinoside - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
